Related Experiment Video
Updated: Jul 11, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Effect of microaneurysms on the anti-VEGF treatment for diabetic macular edema: A retrospective cross-sectional study
Akira Watanabe1, Hirotugu Takashina2, Tadashi Nakano1
1Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan.
Abstract:
Although anti-vascular endothelial growth factor (VEGF) treatment is effective for treating diabetic macular edema (DME), the effect of the microaneurysm (MA) status on the therapeutic efficacy of an anti-VEGF treatment remains unclear. Our current study investigated the effects of the number and the presence or absence of leaking MAs on DME and the efficacy of anti-VEGF therapy. A total of 51 eyes of 47 DME patients were administered anti-VEGF treatment. Fluorescence angiography results were used to determine the number of MAs and the presence or absence of leakage, with these findings matched to the optical coherence tomography maps. The correlation between the number of MAs and the retinal thicknesses and the influence of the leaking MAs was examined in order to definitively determine the effect of the anti-VEGF treatment. There was a correlation between the number of MAs and the retinal thickness of the sector in both the 6 mm (correlation coefficients: 0.42) and 3 mm (0.34) sectors (P < .001). There was also a correlation between the number of MAs and the retinal thickness in both the 6 mm (0.31) and 3 mm (0.24) sectors after undergoing the treatment (P < .01). There was a significant difference between the mean thickness of the leaking versus the non-leaking MAs in the 6 mm (388 ± 87 μm) and 3 mm (477 ± 108 μm) sectors before treatment (P < .01). There was also a significant difference for the retinal thickness between the sectors with and without leaking MAs after the treatment (P < .01). The degree of retinal edema before treatment is associated with the number of MAs and the presence of leaking MAs. Anti-VEGF treatment is less effective for focal macular edema with large numbers of MAs, which includes leaking MAs.
Insights
Microaneurysm (MA) status impacts anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). More MAs and leaking MAs reduce treatment effectiveness, indicating a need for personalized therapeutic strategies.
Area of Science:
- Ophthalmology
- Medical Research
- Diabetic Retinopathy
Background:
- Diabetic macular edema (DME) is a common complication of diabetes.
- Anti-vascular endothelial growth factor (anti-VEGF) therapy is a primary treatment for DME.
- The influence of microaneurysm (MA) characteristics on anti-VEGF treatment efficacy in DME is not fully understood.
Purpose of the Study:
- To investigate the impact of microaneurysm (MA) number and leakage status on diabetic macular edema (DME).
- To evaluate how MA characteristics affect the therapeutic efficacy of anti-vascular endothelial growth factor (anti-VEGF) treatment in DME patients.
Main Methods:
- Retrospective analysis of 51 eyes from 47 DME patients undergoing anti-VEGF treatment.
- Fluorescence angiography to quantify MA number and leakage.
- Optical coherence tomography (OCT) to assess retinal thickness.
- Correlation analysis between MA status, retinal thickness, and treatment outcomes.
Main Results:
- A significant correlation was found between the number of MAs and retinal thickness in both 6mm and 3mm sectors before and after anti-VEGF treatment.
- Leaking MAs were associated with significantly greater retinal thickness compared to non-leaking MAs before and after treatment.
- Anti-VEGF treatment showed reduced effectiveness in cases with a high number of MAs, particularly those with leakage.
Conclusions:
- The degree of retinal edema in DME is associated with the number and leakage status of MAs.
- Anti-VEGF therapy may be less effective for DME characterized by numerous MAs, especially those that are leaking.
- MA status is a critical factor influencing DME treatment outcomes with anti-VEGF agents.

